JP2023526517A5 - - Google Patents
Info
- Publication number
- JP2023526517A5 JP2023526517A5 JP2022571228A JP2022571228A JP2023526517A5 JP 2023526517 A5 JP2023526517 A5 JP 2023526517A5 JP 2022571228 A JP2022571228 A JP 2022571228A JP 2022571228 A JP2022571228 A JP 2022571228A JP 2023526517 A5 JP2023526517 A5 JP 2023526517A5
- Authority
- JP
- Japan
- Prior art keywords
- leucine
- acetyl
- acetazolamide
- aminopyridine
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063028760P | 2020-05-22 | 2020-05-22 | |
| US63/028,760 | 2020-05-22 | ||
| PCT/IB2021/054399 WO2021234642A1 (en) | 2020-05-22 | 2021-05-20 | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526517A JP2023526517A (ja) | 2023-06-21 |
| JP2023526517A5 true JP2023526517A5 (enExample) | 2024-05-29 |
Family
ID=76181172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571228A Pending JP2023526517A (ja) | 2020-05-22 | 2021-05-20 | 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230201150A1 (enExample) |
| EP (1) | EP4153161A1 (enExample) |
| JP (1) | JP2023526517A (enExample) |
| KR (1) | KR20230015433A (enExample) |
| CA (1) | CA3179105A1 (enExample) |
| MX (1) | MX2022014466A (enExample) |
| WO (1) | WO2021234642A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120157593A (zh) * | 2018-12-06 | 2025-06-17 | 内在生物技术有限公司 | 乙酰基-亮氨酸的氘代类似物 |
| MD3989962T2 (ro) | 2019-06-28 | 2025-12-31 | Intrabio Ltd Gb | Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală |
| WO2021144720A1 (en) | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| TW202604470A (zh) * | 2024-06-20 | 2026-02-01 | 美商音特拉拜歐公司 | 乙醯白胺酸用於治療神經發育障礙 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| JP2009269856A (ja) * | 2008-05-07 | 2009-11-19 | Nobufumi Ono | 異常行動防止薬及びこれを含むインフルエンザ治療薬 |
| CA2803166C (en) | 2010-06-25 | 2023-03-07 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| EP2667869A1 (en) * | 2011-01-28 | 2013-12-04 | Acorda Therapeutics, Inc. | Use of potassium channel blockers to treat cerebral palsy |
| TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
| TN2019000033A1 (fr) * | 2016-08-11 | 2020-07-15 | Intrabio Ltd | Agents thérapeutiques pour maladies neurodégénératives |
| US10485790B1 (en) * | 2018-09-13 | 2019-11-26 | Syneurx International (Taiwan) Corp. | Salts of cycloserine compounds and applications thereof |
| WO2021048431A1 (en) * | 2019-09-12 | 2021-03-18 | Amabiotics | Compounds for treating ataxia |
-
2021
- 2021-05-20 KR KR1020227045142A patent/KR20230015433A/ko active Pending
- 2021-05-20 MX MX2022014466A patent/MX2022014466A/es unknown
- 2021-05-20 US US17/999,598 patent/US20230201150A1/en active Pending
- 2021-05-20 JP JP2022571228A patent/JP2023526517A/ja active Pending
- 2021-05-20 EP EP21728642.6A patent/EP4153161A1/en active Pending
- 2021-05-20 WO PCT/IB2021/054399 patent/WO2021234642A1/en not_active Ceased
- 2021-05-20 CA CA3179105A patent/CA3179105A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paik et al. | Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials | |
| JP2004525142A5 (enExample) | ||
| WO2007056232B1 (en) | Methods of using saha and bortezomib for treating cancer | |
| EP1959988B2 (en) | Use of bovine lactoferrin for treating destructive inflammation of mucous membrane | |
| ES2605942T3 (es) | Uso de un derivado de pirazol en el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva crónica | |
| JP2017513908A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2009521424A (ja) | 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤 | |
| JP2025532676A5 (enExample) | ||
| JP2022514537A5 (enExample) | ||
| JP2025525989A5 (enExample) | ||
| JP2023549849A5 (enExample) | ||
| JP2023531930A5 (enExample) | ||
| JP2023509698A5 (enExample) | ||
| JP2025508051A5 (enExample) | ||
| EA028495B1 (ru) | Пероральная композиция для лечения подагры на основе (-)-галофената и колхицина | |
| JP3655636B2 (ja) | Ｈｉｖ−１感染症を予防及び治療するための組成物と方法 | |
| JP2024523123A (ja) | 去勢抵抗性前立腺がんの治療薬の調製におけるスタキオースの使用 | |
| EP3592351A1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| JP2008534621A5 (enExample) | ||
| US20020071814A1 (en) | Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation | |
| CN104510752B (zh) | 紫檀烷苷的医药用途 | |
| WO2023193705A1 (zh) | 西奥罗尼在抗胰腺癌中的用途 | |
| JP2024524933A5 (enExample) | ||
| JPWO2011007866A1 (ja) | 筋強直性ジストロフィー治療薬 |